Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy)

Journal of Biomedicine and Biotechnology

Volumn 2003, Issue 1, 2003, Pages 48-70

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2' EXOMETHANOCARBATHYMIDINE; 4 HYDROXYCYCLOPHOSPHAMIDE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 METHYLPURINE DEOXYRIBOSIDE; 6 METHYLTHIOINOSINE; ACICLOVIR; ALKYLATING AGENT; ANTIFUNGAL AGENT; ANTIMETABOLITE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; CYTOTOXIN; ENZYME; FLUCYTOSINE; FLUDARABINE; FLUOROURACIL; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR ELAIDIC ACID ESTER; IFOSFAMIDE; NUCLEOSIDE PHOSPHORYLASE; PENCICLOVIR; PRODRUG; RALTITREXED; THYMIDINE KINASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; ZIDOVUDINE;

BYSTANDER EFFECT; CELL CYCLE; CELL KILLING; CELL MEMBRANE; CYTOTOXICITY; DIFFUSION; DIFFUSION COEFFICIENT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GAP JUNCTION; GENE THERAPY; HUMAN; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; SUICIDE GENE THERAPY;

EID: 0038685423     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724303209098     Document Type: Review

References (160)

1. Anderson WF. Gene therapy scores against cancer. Nat Med. 2000;6(8):862-863.
2. Denny WA, Wilson WR, Hay MP. Recent developments in the design of bioreductive drugs. Br J Cancer Suppl. 1996;27:S32-S38.
3. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer. 1997;33(7):1005-1016.
4. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002;62(5):1425-1432.
5. De Clercq E. Guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids. 2000;19(10-12):1531-1541.
6. De Clercq E, Andrei G, Snoeck R, et al. Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids. 2001;20(4-7):271-285.
7. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000;60(15):3989-3999.
8. Steffens S, Frank S, Fischer U, et al. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome p450 4B1: applications for prodrug-activating gene therapy. Cancer Gene Ther. 2000;7(5):806-812.
9. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358(9283):727-729.
10. Rubsam LZ, Davidson BL, Shewach DS. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res. 1998;58(17):3873-3882.
11. Thust R, Tomicic M, Klocking R, Wutzler P, Kaina B. Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir. Mutagenesis. 2000;15(2):177-184.
12. Fick J, Barker FG 2nd, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA. 1995;92(24):11071-11075.
13. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther. 1997;8(15):1825-1835.
14. Kianmanesh AR, Perrin H, Panis Y, et al. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 1997;8(15):1807-1814.
15. Eaton JD, Perry MJA, Todryk SM, et al. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther. 2001;8(7):557-567.
16. Kramm CM, Korholz D, Rainov NG, et al. Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient. Neuropediatrics. 2002;33(1):6-9.
17. Rainov NG, Fetell M, Cloughesy T, et al. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11(17):2389-2401.
18. Kokoris MS, Sabo P, Black ME. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. 2000;20(2A):959-963.
19. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001;61(7):3022-3026.
20. Hinds TA, Compadre C, Hurlburt BK, Drake RR. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities. Biochemistry. 2000;39(14):4105-4111.
21. Kokoris MS, Sabo P, Adman ET, Black ME. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 1999;6(8):1415-1426.
22. Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. 2001;61(5):1805-1809.
23. Jones RK, Pope IM, Kinsella AR, Watson AJM, Christmas SE. Combined suicide and granulocytemacrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 2000;7(12):1519-1528.
24. Marples B, Greco O, Joiner MC, Scott SD. Molecular approaches to chemo-radiotherapy. Eur J Cancer. 2002;38(2):231-239.
25. Nishihara E, Nagayama Y, Mawatari F, et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology. 1997;138(11):4577-4583.
26. Atkinson G, Hall SJ. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology. 1999;54(6):1098-2104.
27. Park JY, Elshami AA, Amin K, Rizk N, Kaiser LR, Albelda SM. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Ther. 1997;4(9):909-917.
28. Wildner O, Blaese RM, Candotti F. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. 1999;59(20):5233-5238.
29. Wildner O, Blaese RM, Morris JC. Synergybetween the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Hum Gene Ther. 1999;10(16):2679-2687.
30. Balzarini J, Degreve B, Andrei G, et al. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther. 1998;5(3):419-426.
31. Shaw MM, Gurr WK, Watts PA, Littler E, Field HJ. Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinase-transformed baby hamster kidney cells. Antiviral Chem Chemother. 2001;12:175-186
32. Thust R, Tomicic M, Klocking R, Voutilainen N, Wutzler P, Kaina B. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. Cancer Gene Ther. 2000;7(1):107-117.
33. Tong XW, Engehausen DG, Kaufman RH, et al. Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy. Anticancer Res. 1998;18(2A):713-718.
34. Valerie K, Brust D, Farnsworth J, et al. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther. 2000;7(6):879-884.
35. Hasenburg A, Tong XW, Fischer DC, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol. 2001;83(3):549-554.
36. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment. Anticancer Res. 1999;19(3B):2163-2165.
37. Teh BS, Aguilar-Cordova E, Kernen K, et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int J Radiat Oncol Biol Phys. 2001;51(3):605-613.
38. Shalev M, Kadmon D, Teh BS, et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000;163(6):1747-1750.
39. Basnak I, Otter GP, Duncombe RJ, et al. Efficient syntheses of (E)-5-(2-bromovinyl)-2′-deoxy-4′-thiouridine; a nucleoside analogue with potent biological activity. Nucleosides Nucleotides. 1998;17(1-3):29-38.
40. Hamel W, Zirkel D, Mehdorn HM, Westphal M, Israel MA. (E)-5-(2-bromovinyl)-2′-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase-expressing cells. Cancer Gene Ther. 2001;8(5):388-396.
41. Degreve B, De Clercq E, Balzarini J. Bystander effect of purine nucleoside analogues in HSV-1 tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther. 1999;6(2):162-170.
42. Hlubinova K, Hlavaty J, Altaner C. Human glioma cells expressing herpes simplex virus thymidine kinase gene treated with acyclovir, ganciclovir and bromovinyldeoxyuridine. Evaluation of their activity in vitro and in nude mice. Neoplasma. 2001;48(5):398-406.
43. Grignet-Debrus C, Cool V, Baudson N, Velu T, Calberg-Bacq CM. The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. 2000;7(11):1456-1468.
44. Grignet-Debrus C, Calberg-Bacq CM. Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther. 1997;4(6):560-569.
45. Christians FC, Scapozza L, Crameri A, Folkers G, Stemmer WP. Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. NatBiotechnol. 1999;17(3):259-264.
46. Marquez VE, Siddiqui MA, Ezzitouni A, et al. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J Med Chem. 1996;39(19):3739-3747.
47. Prota A, Vogt J, Pilger B, et al. Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine. Biochemistry. 2000;39(31):9597-9603.
48. Noy R, Ben-Zvi Z, Manor E, et al. Antitumor activity and metabolic activation of N-methanocarbathymidine, a novel thymidine analogue with a pseudosugar rigidly fixed in the northern conformation, in murine colon cancer cells expressing herpes simplex thymidine kinase. Mol Cancer Ther. 2002;1:585-593.
49. Ireton GC, McDermott G, Black ME, Stoddard BL. The structure of Escherichia coli cytosine deaminase. J Mol Biol. 2002;315(4):687-697.
50. Haberkorn U, Oberdorfer F, Gebert J, et al. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J Nucl Med. 1996;37(1):87-94.
51. Stegman LD, Rehemtulla A, Beattie B, et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1999;96(17):9821-9826.
52. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 1998;58(12):2588-2593.
53. Huber BE, Richards CA, Austin EA. VDEPT: an enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Advanced Drug Delivery Reviews. 1995;17:279-292.
54. Nyati MK, Sreekumar A, Li S, et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res. 2002;62(8):2337-2342.
55. Li Z, Shanmugam N, Katayose D, et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 1997;4(2):113-117.
56. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62(3):773-780.
57. Topf N, Worgall S, Hackett NR, Crystal RG. Regional "pro-drug" gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther. 1998;5(4):507-513.
58. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate. 2000;45(2):149-157.
59. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999;59(7):1417-1421.
60. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res. 2000;60(23):6649-6655.
61. Kuriyama S, Mitoro A, Yamazaki M, et al. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand J Gastroenterol. 1999;34(10):1033-1041.
62. Rogers RP, Ge JQ, Holley-Guthrie E, et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther. 1999;7(18):2235-2245.
63. Shirakawa T, Gardner TA, Ko SC, et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol. 1999;162(pt 1):949-954.
64. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 1995;55(21):4808-4812.
65. Adachi Y, Tamiya T, Ichikawa T, et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther. 2000;11(1):77-89.
66. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 2000;7(7):1015-1022.
67. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther. 1997;8(1):73-85.
68. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst. 1998;90(5):370-380.
69. Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, Weichselbaum RR. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 1997;57(19):4205-4209.
70. Pederson LC, Buchsbaum DJ, Vickers SM et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 1997;57(19):4325-4332.
71. Gabel M, Kim JH, Kolozsvary A, Khil M, Freytag S. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int J Radiat Oncol Biol Phys. 1998;41(4):883-887.
72. Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin Oncol. 1999;17(7):2180-2189.
73. Mao C, Cook WJ, Zhou M, Koszalka GW, Krenitsky TA, Ealick SE. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 1997;5(10):1373-1383.
74. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 2000;7(20):1738-1743.
75. Lockett LJ, Molloy PL, Russell PJ, Both GW. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res. 1997;3(11):2075-2080.
76. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998;9(11):1617-1626.
77. Mohr L, Shankara S, Yoon SK, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology. 2000;31(3):606-614.
78. Parker WB, King SA, Allan PW, et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther. 1997;8(14):1637-1644.
79. Krohne TU, Shankara S, Geissler M, et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology. 2001;34(3):511-518.
80. Waxman DJ, Chen L, Hecht JE, Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab Rev. 1999;31(2):503-522.
81. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995;55(3):581-589.
82. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995;1(10):1171-1177.
83. Manome Y, Wen PY, Chen L, et al. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 1996;3(6):513-520.
84. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 1997;57(21):4830-4837.
85. Huang Z, Raychowdhury MK, Waxman DJ. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther. 2000;7(7):1034-1042.
86. Huang Z, Waxman DJ. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther. 2001;8(6):450-458.
87. Zhou D, Lu Y, Steiner MS, Dalton JT. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrob Agents Chemother. 2000;44(10):2659-2663.
88. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998;58(19):4391-4401.
89. Kan O, Griffiths L, Baban D, et al. Direct retroviral delivery of human cytochrome P450 2B6 for genedirected enzyme prodrug therapy of cancer. Cancer Gene Ther. 2001;8(7):473-482.
90. Jounaidi Y, Waxman DJ. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res. 2001;61(11):4437-4444.
91. Karle P, Renner M, Salmons B, Gunzburg WH. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 2001;8(3):220-230.
92. Kammertoens T, Gelbmann W, Karle P, et al. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther. 2000;7(4):629-636.
93. Lohr M, Muller P, Karle P, et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 1998;5(8):1070-1078.
94. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 2000;60(14):3761-3769.
95. Thatcher NJ, Edwards RJ, Lemoine NR, Doehmer J, Davies DS. The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. Cancer Gene Ther. 2000;7(4):521-525.
96. Rainov NG, Dobberstein KU, Sena-Esteves M, et al. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther. 1998;9(9):1261-1273.
97. Mohr L, Rainov NG, Mohr UG, Wands JR. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther. 2000;7(7):1008-1014.
98. Frank S, Steffens S, Fischer U, Tlolko A, Rainov NG, Kramm CM. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy. Cancer Gene Ther. 2002;9(2):178-188.
99. Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bisset GM, Jarman M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem. 1990;33(2):677-681.
100. Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996;56(20):4735-4742.
101. Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther. 2000;7(10):1348-1356.
102. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther. 2000;11(2):285-292.
103. Niculescu-Duvaz I, Friedlos F, Niculescu-Duvaz D, Davies L, Springer CJ. Prodrugs for antibody-and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des. 1999;14(6):517-538.
104. Niclescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, et al. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. J Med Chem. 1998;41(26):5297-5309.
105. Webley SD, Francis RJ, Pedley RB, et al. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer. 2001;84(12):1671-1676.
106. Friedlos F, Davies L, Scanlon I, et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 2002;62(6):1724-1729.
107. Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos F, et al. Self-immolative anthracycline prodrugs for suicide gene therapy. J Med Chem. 1999;42(13):2485-2489.
108. Hamstra DA, Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther. 1999;10(2):235-248.
109. Hamstra DA, Page M, Maybaum J, Rehemtulla A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-α-peptide prodrugs. Cancer Res. 2000;60(3):657-665.
110. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res. 2001;61(13):5078-5082.
111. Ogasawara H, Nishio K, Takeda Y, et al. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells. Jpn J Cancer Res. 1994;85(4):418-425.
112. Kojima A, Hackett NR, Ohwada A, Crystal RG. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest. 1998;101(8):1789-1796.
113. Meck MM, Wierdl M, Wagner LM, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res. 2001;61(13):5083-5089.
114. Farquhar D, Cherif A, Bakina E, Nelson JA. Intensely potent doxorubicin analogues: structure-activity relationship. J Med Chem. 1998;41(6):965-972.
115. Hansch C, Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. New York, NY: Wiley; 1979.
116. Zenno S, Koike H, Tanokura M, Saigo K. Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J Biochem (Tokyo). 1996;120(4):736-744.
117. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) -I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol. 1992;44(12):2289-2295.
118. Parkinson GN, Skelly JV, Neidle S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J Med Chem. 2000;43(20):3624-3631.
119. Lovering AL, Hyde EI, Searle PF, White SA. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7 A, 1.8 A and 2.4 A resolution. J Mol Biol. 2001;309(1):203-213.
120. Knox RJ, Friedlos F, Marchbank T, Roberts JJ. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol. 1991;42(9):1691-1697.
121. Friedlos F, Court S, Ford M, Denny WA, Springer C. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 1998;5(1):105-112.
122. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther. 1997;8(6):709-717.
123. McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 1998;5(8):1061-1069.
124. Green NK, Youngs DJ, Neoptolemos JP, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 1997;4(4):229-238.
125. Djeha AH, Hulme A, Dexter MT, et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 2000;7(5):721-731.
126. Westphal EM, Ge J, Catchpole JR, Ford M, Kenney SC. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo. Cancer Gene Ther. 2000;7(1):97-106.
127. Cui W, Gusterson BA, Clark AJ. Inhibition of myc-dependent breast tumor formation in transgenic mice. Breast Cancer Res Treat. 2002;71(1):9-20.
128. Chung-Faye G, Palmer D, Anderson D, et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res. 2001;7(9):2662-2668.
129. Anlezark GM, Melton RG, Sherwood RF, et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol. 1995;50(5):609-618.
130. Palmer BD, van Zijl P, Denny WA, Wilson WR. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J Med Chem. 1995;38(7):1229-1241.
131. Kestell P, Pruijn FB, Siim BG, Palmer BD, Wilson WR. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5. Cancer Chemother Pharmacol. 2000;46(5):365-374.
132. Palmer BD, Wilson WR, Cliffe S, Denny WA. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem. 1992;35(17):3214-3222.
133. Palmer BD, Wilson WR, Atwell GJ, Schultz D, Xu XZ, Denny WA. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J Med Chem. 1994;37(14):2175-2184.
134. Atwell GJ, Boyd M, Palmer BD, et al. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. Anticancer Drug Des. 1996;11(7):553-567.
135. Friedlos F, Denny WA, Palmer BD, Springer CJ. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J Med Chem. 1997;40(8):1270-1275.
136. Wardman P. Some reactions and properties of nitro radical-anions important in biology and medicine. Environ Health Perspect. 1985;64:309-320.
137. Mauger AB, Burke PJ, Somani HH, Friedlos F, Knox RJ. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem. 1994;37(21):3452-3458.
138. Sykes BM, Hay MP, Bohinc-Herceg D, Helsby NA, O'Connor CJ, Denny WA. Leaving group effects in reductively-triggered fragmentation of 4-nitrobenzyl carbamates. J Chem Soc [Perkin 1]. 2000;(10):1601-1608.
139. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem. 2001;36(7-8):577-595.
140. Sagnou MJ, Howard PW, Gregson SJ, Eno-Amooquaye E, Burke PJ, Thurston DE. Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT. Bioorg Med Chem Lett. 2000;10(18):2083-2086.
141. Lee M, Simpson JE, Woo S, et al. Synthesis of an aminopropyl analog of the experimental anticancer drug tallimustine, and activation of its 4-nitrobenzylcarbamoyl prodrug by nitroreductase and NADH. Bioorg Med Chem Lett. 1997;7:1065-1070.
142. Hay MP, Wilson WR, Denny WA. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg Med Chem Lett. 1999;9(24):3417-3422.
143. Hay MP, Sykes BM, Denny WA, Wilson WR. A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1, 2-dihydro-3H-benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg Med Chem Lett. 1999;9(15):2237-2242.
144. Bailey SM, Knox RJ, Hobbs SM, et al. Investigation of alternative prodrugs for use with E. coli nitroreductase in "suicide gene" approaches to cancer therapy. Gene Ther. 1996;3(12):1143-1150.
145. Wardman P. Indole-3-acetic acids and horseradish peroxidase: a new prodrug/enzyme combination for targeted cancer therapy. Curr Pharm Des. 2002;8(15):1363-1374.
146. Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU. Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther. 2000;7(11):1414-1420.
147. Greco O, Tozer GM, Dachs GU. Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. Int J Radiat Biol. 2002;78(3):173-181.
148. Folkes LK, Greco O, Dachs GU, Stratford MR, Wardman P. 5-fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy. Biochem Pharmacol. 2002;63(2):265-272.
149. Tamiya T, Ono Y, Wei MX, Mroz PJ, Moolten FL, Chiocca EA. Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 1996;3(3):155-162.
150. Ono Y, Ikeda K, Wei MX, Harsh GR 4th, Tamiya T, Chiocca EA. Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy. Hum Gene Ther. 1997;8(17):2043-2055.
151. Fonseca MJ, Storm G, Hennink WE, Gerritsen WR, Haisma HJ. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy. J Gene Med. 1999;1(6):407-414.
152. Weyel D, Sedlacek HH, Muller R, Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 2000;7(3):224-231.
153. Heine D, Muller R, Brusselbach S. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Ther. 2001;8(13):1005-1010.
154. Bakina E, Farquhar D. Intensely cytotoxic anthracycline prodrugs: galactosides. Anticancer Drug Des. 1999;14(6):507-515.
155. Bakina E, Wu Z, Rosenblum M, Farquhar D. Intensely cytotoxic anthracycline prodrugs: glucuronides. J Med Chem. 1997;40(25):4013-4018.
156. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer. 1999;80(11):1726-1733.
157. Kato Y, Matsukawa S, Muraoka R, Tanigawa N. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer. 1997;75(4):506-511.
158. Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer. 1995;72(3):669-675.
159. Hoffman RM, Erbe RW. High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA. 1976;73(5):1523-1527.
160. Miki K, Xu M, Gupta A, et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 2001;61(18):6805-6510.